These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 7815875)

  • 1. Factor V Leiden mutation and venous thrombosis.
    Davies KA; Ireland H; Athanassiou P; Loizou S; Lane D; Walport MJ
    Lancet; 1995 Jan; 345(8942):132-3. PubMed ID: 7815875
    [No Abstract]   [Full Text] [Related]  

  • 2. Factor V Leiden mutation and venous thrombosis.
    Hatake K; Miura Y
    Lancet; 1995 Jan; 345(8942):133. PubMed ID: 7815876
    [No Abstract]   [Full Text] [Related]  

  • 3. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation.
    Vandenbroucke JP; Koster T; Briët E; Reitsma PH; Bertina RM; Rosendaal FR
    Lancet; 1994 Nov; 344(8935):1453-7. PubMed ID: 7968118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor V Leiden, antiphospholipid antibodies and thrombosis in systemic lupus erythematosus.
    Fijnheer R; Horbach DA; Donders RC; Vilé H; von Oort E; Nieuwenhuis HK; Gmelig-Meijling FH; de Groot PG; Derksen RH
    Thromb Haemost; 1996 Oct; 76(4):514-7. PubMed ID: 8902988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral contraception and factor V Leiden mutation in relation to localization of deep vein thrombosis.
    Andersen BS; Olsen J
    Thromb Res; 1998 May; 90(4):191-4. PubMed ID: 9692618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of thrombosis in patients with antiphospholipid antibodies and factor V Leiden mutation.
    Pablos JL; Caliz RA; Carreira PE; Atsumi T; Serrano L; Amengual O; Santiago B; Khamashta MA; Hughes GR; Gomez-Reino JJ
    J Rheumatol; 1999 Mar; 26(3):588-90. PubMed ID: 10090167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Factor V leiden and venous thromboembolism in a woman taking second generation oral contraceptives: a case report].
    Undas A; Sanak M; Jankowski M; Undas R; Musiał J; Szczeklik A
    Ginekol Pol; 1999 Feb; 70(2):93-7. PubMed ID: 10349814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden.
    Hirsch DR; Mikkola KM; Marks PW; Fox EA; Dorfman DM; Ewenstein BM; Goldhaber SZ
    Am Heart J; 1996 Jun; 131(6):1145-8. PubMed ID: 8644593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Oral contraception increases the chance of venous thrombosis in factor V Leiden mutation].
    Vandenbroucke JP; Briët E; Helmerhorst F; van der Meer FJ
    Ned Tijdschr Geneeskd; 1995 May; 139(21):1067-71. PubMed ID: 7783798
    [No Abstract]   [Full Text] [Related]  

  • 10. [Breakthrough in thrombosis research--can the use of contraceptive pills be safer than it used to be?].
    Lähteenmäki P
    Duodecim; 1995; 111(22):2097-8. PubMed ID: 9841168
    [No Abstract]   [Full Text] [Related]  

  • 11. A decrease in antiphospholipid antibodies before a thrombotic event.
    Praprotnik S; Bozic B
    Clin Rheumatol; 1996 May; 15(3):298-300. PubMed ID: 8793265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Leiden, G20210A mutations in prothrombin gene and antiphospholipid antibodies in systemic lupus erythematosus and antiphospholipid syndrome].
    Reshetniak TM; Patrushev LI; Stukacheva EA; Miroshnikov AI; Tikhonova TL; Nasonov EL; Alekberova ZS
    Ter Arkh; 2000; 72(5):34-8. PubMed ID: 11109617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP
    Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor V Leiden: should we screen oral contraceptive users and pregnant women?
    Vandenbroucke JP; van der Meer FJ; Helmerhorst FM; Rosendaal FR
    BMJ; 1996 Nov; 313(7065):1127-30. PubMed ID: 8916702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor V Leiden increases the risk of thrombosis in patients with antiphospholipid antibodies.
    Simantov R; Lo SK; Salmon JE; Sammaritano LR; Silverstein RL
    Thromb Res; 1996 Dec; 84(5):361-5. PubMed ID: 8948063
    [No Abstract]   [Full Text] [Related]  

  • 16. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives.
    Martinelli I; Sacchi E; Landi G; Taioli E; Duca F; Mannucci PM
    N Engl J Med; 1998 Jun; 338(25):1793-7. PubMed ID: 9632445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated protein C resistance--a major risk factor for thrombosis.
    Rosén SB; Sturk A
    Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor V Leiden, prothrombin gene mutation, and thrombosis risk in patients with antiphospholipid antibodies.
    Chopra N; Koren S; Greer WL; Fortin PR; Rauch J; Fortin I; Senécal JL; Docherty P; Hanly JG
    J Rheumatol; 2002 Aug; 29(8):1683-8. PubMed ID: 12180730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. End of the line for "third-generation-pill" controversy?
    Vandenbroucke JP; Rosendaal FR
    Lancet; 1997 Apr; 349(9059):1113-4. PubMed ID: 9113005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should coagulation tests be used to determine which oral contraceptive users have an increased risk of thrombophlebitis?
    Comp PC
    Contraception; 2006 Jan; 73(1):4-5. PubMed ID: 16371288
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.